Association of promoter hypermethylation of the RASSF1A gene with prognostic parameters in endometrial cancer

RASSF1A is a tumor suppressor gene that is frequently hypermethylated in various human cancers. In the present study, we examined RASSF1A methylation status in 70 patients with endometrial cancer to search for correlations between the promoter hypermethylation of RASSF1A and the clinicopathologic pa...

Full description

Saved in:
Bibliographic Details
Published inOncology research Vol. 16; no. 4; p. 205
Main Authors Jo, Hoenil, Kim, Jae Weon, Kang, Gyeong Hoon, Park, Noh-Hyun, Song, Yong-Sang, Kang, Soon-Beom, Lee, Hyo-Pyo
Format Journal Article
LanguageEnglish
Published United States 01.01.2006
Subjects
Adult
Aged
Disease-Free Survival
DNA Methylation
Endometrial Neoplasms - genetics
Endometrial Neoplasms - pathology
Endometrial Neoplasms - surgery
Female
Genes, Tumor Suppressor
Humans
Middle Aged
Promoter Regions, Genetic
Tumor Suppressor Proteins - genetics
Online AccessGet more information

Cover

More Information
Summary:RASSF1A is a tumor suppressor gene that is frequently hypermethylated in various human cancers. In the present study, we examined RASSF1A methylation status in 70 patients with endometrial cancer to search for correlations between the promoter hypermethylation of RASSF1A and the clinicopathologic parameters. Thirty-six of 70 endometrial cancers demonstrated hypermethylation of the RASSF1A promoter. Advanced stage disease (FIGO stage III, IV), lymph node involvement, and high grade (G3) are more frequent in patients with RASSF1A hypermethylation than in those without. We also observed a higher incidence of recurrences and lower disease-free survival (DFS) in patients with RASSF1A hypermethylation (77.8% and 97.0% at 5 years for methylated and unmethylated patients, respectively, p = 0.039). Our results suggest that RASSF1A hypermethylation might be a useful indicator of tumor aggressiveness in endometrial cancer patients.
ISSN:0965-0407
DOI:10.3727/000000006783981125